Switzerland-based Novartis announced plans on 19 November to build a new manufacturing hub in North Carolina, US, which is part of a previously announced $23 billion investment in the country over the next five years. The outlays will feature new facilities in Durham to manufacture biologics and sterile packaging; a site in Morrisville to produce solid dosage tablets and capsules; and an expansion of an existing site in Durham to support the sterile filling of biologics into syringes and vials.
